title: Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis.
abstract: This report describes our experience with reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) using matched sibling and unrelated donors (MUDs) for treatment of myelofibrosis (MF). Nine patients with MF (median age, 54 years) were treated with RIC allogeneic HCT using MUDs for 7 of the 9 patients and sibling donors for 2 patients. By the Lille classification, 4 patients were characterized as having high risk, 4 as having intermediate risk, and 1 as having low risk. The RIC regimen consisted of fludarabine and a single dose of total body irradiation for the first patient and fludarabine/melphalan for the remaining 8 patients. Granulocyte colony-stimulating factor-primed peripheral blood stem cells (PBSCs) were used for all but 1 patient who received a total of 3 products because of graft failure, of which 2 were bone marrow cells and the third was PBSCs. Prophylaxis against graft-versus-host disease consisted of cyclosporin/mycophenolate with or without methotrexate. Seven patients were successfully engrafted with white blood cells, with an absolute neutrophil count > or =500 by a median of day +15 (range, 10-21 days). At the time of final fluorescence in situ hybridization and/or short tandem repeat analysis, 8 of 9 patients were chimeric, with 96%-100% donor cells and/or DNA. Five of the 9 patients were alive at the time of final contact, with a median follow-up of 32.2 months for the living patients. Overall survival probability at 1 year was 55.6% (95% confidence interval, 31.3%-77.4%). These results suggest that RIC MUD HCT using PBSCs can be an effective treatment for older patients with MF.
authors.affiliation: Division of Hematology/Hematopoietic Cell Transplant, City of Hope Cancer Center, Duarte, California 91010, USA. dsnyder@coh.org
authors.forename: David S
authors.initials: DS
authors.lastname: Snyder
authors.forename: Joycelynne
authors.initials: J
authors.lastname: Palmer
authors.forename: Anthony S
authors.initials: AS
authors.lastname: Stein
authors.forename: Vinod
authors.initials: V
authors.lastname: Pullarkat
authors.forename: Firoozeh
authors.initials: F
authors.lastname: Sahebi
authors.forename: Sandra
authors.initials: S
authors.lastname: Cohen
authors.forename: Nayana
authors.initials: N
authors.lastname: Vora
authors.forename: Karl
authors.initials: K
authors.lastname: Gaal
authors.forename: Ryo
authors.initials: R
authors.lastname: Nakamura
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Forman
mesh_terms: D000368:Aged; D005260:Female; D006085:Graft Survival / Q000276:immunology; D006086:Graft vs Host Disease; D006801:Humans; D053208:Kaplan-Meier Estimate; D017567:Karnofsky Performance Status; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D055728:Primary Myelofibrosis / Q000628:therapy*; D012189:Retrospective Studies; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome